Method of treating neurodegenerative diseases
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorsHermona Soreq, Amit Berson
Life of this patent
Estimating the term…
Abstract
An agent which upregulates an amount or activity of a heterogeneous nuclear ribonucleoproteins A/B (hnRNP A/B) polypeptide is disclosed, for use in treating a neurodegenerative disease. Pharmaceutical compositions comprising same are also disclosed.
Claims14
(canceled)
A method of treating a neurodegenerative disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which upregulates an amount or activity of heterogeneous nuclear ribonucleoproteins A/B (hnRNP A/B) in a brain of the subject, thereby treating the neurodegenerative disease.
A pharmaceutical composition comprising miR132 or a miR211 antagonist or both as an active agent and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.